Infinity dumps lung cancer drug after PhII trial fails survival test – FierceBiotech

by lowes1 on September 25, 2013


MedCity News
Infinity dumps lung cancer drug after PhII trial fails survival test
FierceBiotech
Infinity Pharmaceuticals ($INFI) had some more bad news to report this morning. Investigators said that its Hsp90 inhibitor retaspimycin hydrochloride failed a mid-stage study for non-small cell lung cancer. Investigators say that the treatment failed
Infinity Pharma's cancer drug fails mid-stage trial goalsReuters
Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride MarketWatch (press release)

all 6 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: